Drug

SPC-15

Targeted prophylactic treatment—Stress-induced affective disorders

Columbia University CELA

Market Opportunity

Targeted prophylactic treatment—Stress-induced
affective disorders

  • 26% of Americans 18+ suffer from anxiety, PTSD and other disorders
  • This number has escalated post-COVID-19
  • U.S. market for relevant drugs expected to reach $13 billion by 2027

Technology

  • Metabolomic biomarkers predict response to pharmacological treatments
  • Liquid nasal formulation
Previous Drug
Next Drug

Applications

  • Sponsored Research Agreement with Columbia University
  • Prevention of stress-induced affective disorders
  • Increasing stress resilience in military, first responders, and other populations at high risk of PTSD
  • Predicting the level of severity or progression such disorders
  • Molecular targets for use in drug discovery of innovative treatments

Get more information on Silo Pharma. Sign up for email alerts online.

SIGN UP